Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
768.8 EUR | 0.00% | +2.74% | +45.61% |
06/06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
06/06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
Sales 2024 * | 4.3TCr 3.94TCr 3,58500Cr | Sales 2025 * | 5.26TCr 4.83TCr 4,39000Cr | Capitalization | 75TCr 69TCr 62,88900Cr |
---|---|---|---|---|---|
Net income 2024 * | 1.19TCr 1.09TCr 1LCr | Net income 2025 * | 1.66TCr 1.52TCr 1,38100Cr | EV / Sales 2024 * | 18 x |
Net Debt 2024 * | 1.81TCr 1.66TCr 1,50700Cr | Net Debt 2025 * | 1.5TCr 1.38TCr 1,25100Cr | EV / Sales 2025 * | 14.6 x |
P/E ratio 2024 * |
62.6
x | P/E ratio 2025 * |
45.1
x | Employees | - |
Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 week | +3.02% | ||
Current month | +3.46% | ||
1 month | +9.31% | ||
3 months | +8.38% | ||
6 months | +42.20% | ||
Current year | +47.18% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/23/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
Date | Price | Change |
---|---|---|
06/24/06 | 777.1 | +1.08% |
05/24/05 | 768.8 | +0.29% |
04/24/04 | 766.6 | +0.50% |
03/24/03 | 762.8 | +1.56% |
31/24/31 | 751.1 | -0.42% |
Delayed Quote Börse Stuttgart, June 07, 2024 at 01:19 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.42% | 61TCr | |
-6.58% | 35TCr | |
+19.72% | 33TCr | |
+8.78% | 29TCr | |
+11.92% | 22TCr | |
-2.62% | 21TCr | |
+0.03% | 17TCr | |
+6.13% | 16TCr | |
+1.39% | 12TCr |
- Stock Market
- Equities
- LLY Stock
- LLY Stock